论文部分内容阅读
Inspired by the recent success of two ADCs (Adcetris(R) in 2011 and Kadcyla(R) in 2013), virtually every major pharmaceutical company with an oncology program now has an initiative on ADCs.Among the 60+ ADCs currently in development, however, nearly 50 of them use the same variants of auristatin and maytansine, the two payloads used in Adcetris(R) and Kadcyla(R), respectively.